Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma

NCT00425347 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Facet Biotech